FLT3 mutation

@TheEBMT @EHA_Hematology Hot topic FLT3 mutated AML FLT3: - Transmembrane TK - Gene mapped on Chr. 13 - Normally expressed by hematopoietic stem, but not in mature cells - Promoting cell survival, proliferation, and differentiation (@HematoUptodate)

“I do think this [approval] represents a step forward for patients who have the FLT3 mutation in association with their [AML] over the previous standard, midostaurin [Rydapt],” study author @MikkaelSekeres, MD, said in an interview with CancerNetwork ahead of the approval. https://t.co/nqtM6JI5dz (@CancerNetwrk)

Gilteritinib Shows RFS Benefit as Maintenance, Posttransplant Therapy in MRD+ FLT3-Mutant AML @KimmelCancerCtr @EHA_Hematology #EHA2023 #leusm https://t.co/2W8q3TZlm8 (@OncLive)

ICYMI: Venetoclax plus gilteritinib was linked with high response rates in relapsed or refractory FLT3-mutated AML, regardless of prior FLT3 inhibitor exposure, according to a phase Ib study by @Daver_Leukemia of @MDAndersonNews and colleagues. 📚: https://t.co/AaC4tAjN90 (@Blood_Cancers)

ICYMI: Venetoclax plus gilteritinib was associated with high response rates in relapsed or refractory FLT3-mutated AML, regardless of prior FLT3 inhibitor exposure, according to a phase Ib study by @Daver_Leukemia of @MDAndersonNews and colleagues. 📚: https://t.co/AaC4tAjN90 (@Blood_Cancers)

Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions https://t.co/pXk9zm3Ee0 #mdpicancers via @Cancers_MDPI #leum (@smbenlazar)

Venetoclax plus gilteritinib was associated with high response rates in patients with relapsed or refractory FLT3-mutated AML, regardless of prior FLT3 inhibitor exposure, according to a phase Ib study by @Daver_Leukemia of @MDAndersonNews and colleagues. https://t.co/1F1d05CHrJ (@Blood_Cancers)

#Gilteritinib plus #azacitidine yielded higher CRc rates than azacitidine treatment alone among patients with #FLT3-mutated #AML unable to receive intensive #chemotherapy. Click the link to learn more about Dr Wang's research! @EuniceWangMD https://t.co/WDGAdS0zgV (@OncLearnNetwork)

What do acute myeloid leukemia (#AML) patients need to know about FLT3 mutation? Dr. Naval Daver @Daver_Leukemia of @MDAndersonNews shares information. https://t.co/ohnn4OZTFq #leusm #AMLsm (@power4patients)

The final session from the 2023 ‘Controversies in Hematologic Malignancies’ brought exciting glimpses into the future of FLT3-mutated AML and advanced-stage CML therapy. ⁦@PratzKW⁩ ⁦@MWDeininger⁩ ⁦@mcw_oncology⁩ ⁦@BloodResearchWI⁩ (@ksbcarlson)

📣Our latest @TheIACH Journal Club: Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Now available on-demand! View the full library for FREE⬇️ https://t.co/rI1oBq60nF @Mohty_EBMT @Daver_Leukemia (@TheIACH)

📣Join us NOW! >> Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia FREE registration✍️ https://t.co/7dlhs8OSF0 @Mohty_EBMT @Daver_Leukemia (@TheIACH)

📣Join us TODAY for @TheIACH Journal Club: Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia FREE registration✍️ https://t.co/7dlhs8OSF0 Tuesday, February 7, 2023 8pm Paris, 2pm NY @Mohty_EBMT @Daver_Leukemia (@TheIACH)

📣Join us TOMORROW for @TheIACH Journal Club: Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia FREE registration✍️ https://t.co/7dlhs8OSF0 Tuesday, February 7, 2023 8pm Paris, 2pm NY @Mohty_EBMT @Daver_Leukemia (@TheIACH)

📣Join us for the upcoming Journal Club: Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia FREE registration✍️ https://t.co/7dlhs8OSF0 Tuesday, February 7, 2023 8pm Paris, 2pm NY @Mohty_EBMT @Daver_Leukemia (@TheIACH)

📣Join us for the upcoming Journal Club: Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia FREE registration✍️ https://t.co/7dlhs8Pquy Tuesday, February 7, 2023 8pm Paris, 2pm NY @Mohty_EBMT @Daver_Leukemia (@TheIACH)

This is a young fit pt with ELN fav AML (NPM1 mutant, FLT3 ITD negative), if achieves MRD_neg CR1, would not necessarily txp. NPM1 is now AML defining (regardless of blasts) so standard IC, not HMA/ven (experimental in this setting). (@LuskinMarlise)

PVEK+VEN+AZA demonstrated broad anti-leukemic activity in R/R and frontline AML;including specifically VEN-naïve, first relapse, and those with IDH2 and FLT3 mutations #KuASHreview #USMIRC #medtwitter #MedEd @KUcancercenter (@Abdallah81MD)

We meet the occasional AML pt with a FLT3 mutation outside the classic ITD/TKD sites. A common one is FLT3 N676K. Check out our new @UChicagoLeuk analysis of this atypical variant's responsiveness to FLT3i @michaelwd @UCCancerCenter @UCHemOncFellows https://t.co/1V2zGyqqSd (@RoloffGreg)

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia | Journal of Clinical Oncology https://t.co/s6nbSICWfV (@SCTNB)

This looks like acute promyelocytic leukaemia with possible NPM1/flt3 mutation. (@OgochukwuIzu)

AML cup like blasts with NPM mutation. FLT3 mutation may be or not present. (@annamerino52)

Excellent Results for Triplet Regimen in FLT3-Mutated #AML Nicholas Short, @NicholasShortMD of @MDAndersonNews #Leukemia https://t.co/NayhKwfTCz via @physicianswkly #leusm (@Lisa_Palacios)

V-FAST Subgroup Analysis: CPX-351 + Midostaurin in Newly Diagnosed AML by FLT3 Mutation #ASH22 #AML #leusm (@smbenlazar)

Phase I/II Trial of Triplet Combination of Gilteritinib + Azacitidine/Venetoclax in Patients With FLT3-Mutated AML: Updated Results #ASH22 #leusm #AMLsm (@smbenlazar)

Glad to have presented with Dr. @FadiHaddad_MD our abstract "Evaluation of Emergent of FLT3 mutation at relapse in Patients with WT-FLT3 AML" at #ASH22 @MusaYilmazMD @DrHKantarjian @ASH_hematology @HemOncFellows (@GeorgioMedawar)

Dr. @NicholasShortMD presenting the updates of the phase I/II study of AZA+VEN+Gilteritinib treatment for FLT3-mutated #AML at #ASH22 (@ABidikianMD)

@NicholasShortMD presents an update on triplet tx w/ aza/ven/gilt in newly dx FLT3-mutated AML or R/R AML or HR MDS/CMML -> aza d1-7, gilt 80-120 mg d1-28 (less myelosupp w/ 80 mg dose), ven 1-28 (hold early if <5% blasts d14) -> 27 newly dx and 20 R/R pts. #leusm #ASH22 1/2 (@MarkGeyerMD)

Congratulations to ⁦@UCSFCancer⁩ super 🌟⁦@vekennedy⁩ on her amazing oral presentation at #ASH22 on single cell sequencing of FLT3 mutated AML treated w/ Gilt/ven. Fantastic work! ⁦@SmithLabSF⁩ @ASH_hematology⁩ ⁦ (@KellySchoenbeck)

Great presentation by @NicholasShortMD on the updated results of the Aza+Ven+Gilt triplet in FLT3 mutated AML ➡️ impressive 1yr-OS of 80%. FLT3 TKD continues to do better than FLT3 ITD. #ASH22 (@jayastuMD)

A pleasure to catch up with @NicholasShortMD of @MDAndersonNews here at #ASH22, who spoke on updated results from a Phase I/II study of azacitidine, venetoclax & gilteritinib in patients with FLT3-mutated AML & more! @ASH_Hematology #HemOnc #LeuSM #ALLsm #AMLsm #ImmunoOnc (@VJHemOnc)

QUAZAR AML-001 trial 📖Pts in remission treated w Oral-AZA had better OS&RFS vs placebo regardless of NPM1 or FLT3 mutational status at AML dx 📖Oral-AZA conferred OS and/or RFS benefits in pts w favorable (NPM1mut,no MRD) or adverse (FLT3mut, MRD+) prognostic AML features #leusm (@dawood_findakly)

Quizartinib + CT vs Placebo + CT in Newly Diagnosed FLT3-Mutant #AML (@smbenlazar)

ELN Guidelines: Intensive Therapy for Fit Patients With #AML and FLT3 Mutations (@smbenlazar)

Doublet vs Triplet FLTi therapy in older/unfit patients with FLT3 mutated #AML https://t.co/SjOUl1VS4e #leusm (@smbenlazar)

Gilteritinib vs chemotherapy for patients with R/R FLT3-mutation–positive #AML https://t.co/BepotmtERH #leusm (@smbenlazar)

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia https://t.co/QzCMQf8qhd #AML #leusm (@smbenlazar)

⚠️FLT3 mutation status in acute myeloid leukemia can change between diagnosis & relapse ➡️ Always check for FLT3 mutations at the time of relapse. Full data will be presented at #ASH22 @MusaYilmazMD @GeorgioMedawar @DrHKantarjian @Daver_Leukemia @NicholasShortMD @doctorpemm (@FadiHaddad_MD)

Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated #AML https://t.co/HRZC6bPj9X #ASH22 (@smbenlazar)

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia https://t.co/40JEzYThu9 #ASH22 #leusm (@smbenlazar)

Gilteritinib Maintenance Therapy Post-Allogenic Stem-Cell Transplantation Improves the Prognosis of Patients with FLT3-Mutated #AML https://t.co/3g67ob9IgX #ASH22 #leusm (@smbenlazar)

Outcomes with the doublets (aza+ven or aza+gilt) are suboptimal. I think the future will be a triplet (aza+ven+FLT3i/gilteritinib), which hopefully can be curative even for many older pts with FLT3-mutated AML. I look forward to showing updated data from our study at ASH. (@NicholasShortMD)